Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06165016
Other study ID # STU00218660
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 14, 2024
Est. completion date June 1, 2027

Study information

Verified date April 2024
Source Northwestern University
Contact Mary McDermott, MD
Phone 13125036419
Email mdm608@northwestern.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LIGHT PAD Trial is a Phase II multi-centered randomized clinical trial to collect preliminary data to test whether daily far red light treatment of the lower extremities in people with PAD improves six-minute walk distance, lower extremity perfusion, and ischemia-related damage in gastrocnemius muscle at four-month follow-up, compared to a sham control. Participants will complete 10 minutes of twice daily home treatment with either far red light or a sham light for four months.


Description:

The LIGHT PAD Trial is a Phase II multi-centered randomized clinical trial to collect preliminary data to test whether daily far red light treatment of the lower extremities in people with PAD improves six-minute walk distance, lower extremity perfusion, and ischemia-related damage in gastrocnemius muscle at four-month follow-up, compared to a sham control. Participants will complete 10 minutes of twice daily home treatment with either far red light or a sham light for four months. Participants with PAD will be randomized at one of two centers: Northwestern University (PI: MM McDermott, MD) and the University of Alabama (PI: Nicole Lohr MD, PhD) to daily far red light or sham control for four months. The primary outcome, change in six-minute walk, will be measured at four month follow-up, immediately after the final administration of far red light or sham. In secondary and exploratory aims, investigators will distinguish between acute and chronic effects of far red light on six-minute walk, measure the effects of far red light on patient-reported outcomes, and delineate biologic pathways by which far red light improves walking performance in PAD, by measuring change in plasma nitrite and nitrosothiols, gastrocnemius muscle perfusion (MRI arterial spin labeling) and gastrocnemius muscle health and mitochondrial activity. If the proposed hypotheses are supported by this Phase II trial, results will be used to design a definitive randomized trial of far red light for people with PAD. To achieve the specific aims, investigators will randomize 32 participants age 50 and older with PAD to one of two groups: far red light therapy or sham therapy. Participants will be followed for four months.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date June 1, 2027
Est. primary completion date January 30, 2027
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria. First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as: 1. An ABI <= 0.90 at baseline. 2. Vascular lab evidence of PAD (such as a toe brachial pressure < 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities. 3. An ABI of >0.90 and <= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test. Exclusion Criteria: 1. Above- or below-knee amputation 2. Critical limb ischemia defined as an ABI <0.30 or <0.40 with symptoms of rest pain 3. Wheelchair confinement or requiring a walker to ambulate 4. Walking is limited by a symptom other than PAD 5. Current foot ulcer on bottom of foot 6. Failure to successfully complete the study run-in 7. Planned major surgery, coronary or leg revascularization during the next four months 8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months 9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.] 10. Mini-Mental Status Examination (MMSE) score < 23 11. Non-English speaking 12. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] 13. Visual impairment that limits walking ability. 14. Six-minute walk distance of <400 feet or >1700 feet. 15. Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months. 16. Unwilling to avoid red light therapy outside of study participation. 17. Baseline blood pressure <100/45. 18. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Study Design


Intervention

Device:
Far red light therapy
All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.
Sham light therapy
All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. A study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Plasma nitrite Acute change in plasma abundance of nitrite Measured before and within five minutes after the first light treatment
Other Plasma nitrite Four- month changes in plasma abundance of nitrite Measured before and within five minutes after the final light treatment at four-month follow up
Other Plasma Nitrosothiols Changes in plasma abundance of nitrosothiols Measured before and within five minutes after the first light treatment
Other Plasma Nitrosothiols Changes in plasma abundance of nitrosothiols Measured before and within five minutes after the final light treatment at four-month follow up.
Other Gastrocnemius Muscle Capillary Density Four month changes in gastrocnemius muscle capillary density Measured at baseline and four-month follow up
Other Gastrocnemius Muscle Myofiber Size Four month changes in gastrocnemius muscle myofiber size Measured at baseline and four-month follow up
Other Gastrocnemius Muscle COX Enzyme Activity Four month changes in gastrocnemius muscle COX enzyme activity Measured at baseline and four-month follow up
Other Gastrocnemius Muscle Abundance of Satellite Cells Four month changes in gastrocnemius muscle abundance of satellite cells Measured at baseline and four-month follow up
Other Gastrocnemius Muscle Abundance of Myofibers with Central Nuclei Four month changes in gastrocnemius muscle abundance of myofibers with central nuclei Measured at baseline and four-month follow up
Other Walking Impairment Questionnaire (WIQ) Speed Score Four month changes in the WIQ speed score (0-100 score, 100-best) Baseline and four-month follow-up
Other Walking Impairment Questionnaire (WIQ) Stair Climbing Score Four month changes in WIQ stair climbing score (0-100 score, 100-best). Baseline and four month follow-up
Primary Six-Minute Walk Distance Four month change in six-minute walk distance Measured at baseline and 4 month follow-up
Secondary Walking Impairment Questionnaire Distance (WIQ) Score Four month change in the WIQ distance score. Score range 0-100, 100 is best Measured at baseline and 4 month follow-up
Secondary Six-Minute Walk Distance Acute change in six-minute walk distance after first light therapy Measured immediately after the first light treatment (within 15 minutes after the first treatment, acute effect)
Secondary Six-minute walk distance. Four month change in 6-minute walk, measured 24 hours after last treatment. Measured at 4-month follow-up, 24 hours after the final treatment.
Secondary Calf muscle perfusion Changes in calf muscle perfusion at 3 Tesla measured with arterial spin labeling with MRI and post-cuff occlusion hyperemia Measured at baseline and four-month follow up
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A